MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Frontiers In Oncology

  • September 7, 2026
Exercise Interventions for Patients with Brain Tumors: A Comprehensive Review
  • Arooba Iqbal
  • L. Nicolas Gonzalez Castro
  • September 7, 2026

Objective: To synthesize available literature concerning physical exercise and the overall health of patients with brain tumors, addressing effects on motor fun

...more

Frontiers In Immunology

  • September 7, 2026
Identifying Risk Factors for Allergic Rhinitis in Pediatric Populations: A Comprehensive Review of Systematic Reviews and Meta-Analyses
  • Yuzhu Dou
  • Jinyi Li
  • Xueyan Qiu
  • Pengchen Wu
  • Yaqi Wang
  • Mei Chen
  • Zhengjiu Cui
  • Fei Luo
  • Siming Zhai
  • Tao Li
  • Qigang Dai
  • Bin Yuan
  • September 7, 2026
  1. The review identified 75 risk factors for allergic rhinitis in children, with 22 increasing risk and 7 considered protective.
  2. Evidence quality for most identified risk factors was low or very low, with only one factor supported by moderate-quality evidence.
  3. Higher risk factors included early-life antibiotic use, cesarean section, maternal smoking, and diagnoses of ADHD and ASD.
  4. Protective factors against allergic rhinitis included pet exposure, raw milk and fish consumption, and having multiple siblings.
  5. The review emphasizes the need for more rigorous studies to strengthen the evidence base for clinical and public health interventions.
...more

Frontiers In Medicine

  • September 7, 2026
Comparative Evaluation of GeneXpert MTB/RIF, TB-DNA PCR, and T-SPOT.TB in Diagnosing Paucibacillary Pulmonary Tuberculosis: A Triple-Modality Approach
  • Xiaohong Ji
  • Yu Yi
  • Hongyan Zhou
  • Xiao Chen
  • Huilin Zhong
  • Zijun Ji
  • Ting Guo
  • September 7, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Frontiers In Medicine

  • September 7, 2026
Establishing a Collaborative Respiratory Transition Framework for Pediatric and Adult Patients
  • Sara Manti
  • Paolo Ruggeri
  • September 7, 2026

Objective: To propose a structured and formalized transition framework for pediatric patients with chronic respiratory diseases moving to adult care, addressing

...more

Frontiers In Immunology

  • September 7, 2026
Impact of High-Intensity Aerobic Exercise on Immune Cell Dynamics and Cytokine Levels in Prostate Cancer Patients Undergoing Active Surveillance: Insights from the ERASE Randomized Controlled Trial
  • Dong-Woo Kang
  • Dhruvesh Patel
  • Catherine J. Field
  • Normand G. Boulé
  • Adrian S. Fairey
  • Keri L. Schadler
  • Kerry S. Courneya
  • September 7, 2026
  1. The ERASE trial evaluated the effects of high-intensity interval training (HIIT) on immune cell dynamics in prostate cancer patients under active surveillance.
  2. Fifty-two men with localized prostate cancer were randomized into HIIT or usual care, with HIIT consisting of three sessions weekly for 12 weeks.
  3. HIIT significantly increased the proportion of the NK-cell subset and PBMC-mediated cytotoxicity compared to usual care.
  4. Plasma levels of IL-4 and IL-12p70 were significantly reduced in the HIIT group, while other leukocyte populations showed no significant differences.
  5. The study's findings are exploratory and require confirmation in larger studies due to the design and multiple comparisons involved.
...more

Frontiers In Surgery

  • September 7, 2026
Comparative Analysis of Two Instillation Protocols of Intravesical Hyaluronic Acid and Chondroitin Sulphate for Women with Recurrent Urinary Tract Infections: A Prospective Multicenter Study
  • Marilena Gubbiotti
  • Alessandro Giammò
  • Enrico Ammirati
  • Annarita Cicalese
  • Elisabetta Costantini
  • Ester Illiano
  • Vincenzo Li Marzi
  • Mara Bacchiani
  • Leonardo Martino
  • Vito Mancini
  • Stefano Rosadi
  • September 7, 2026
  1. The study evaluated two intravesical instillation protocols of hyaluronic acid and chondroitin sulphate for women with recurrent urinary tract infections.
  2. A total of 140 women participated, with 70 assigned to each of the two treatment groups over a 12-month follow-up period.
  3. Both treatment groups showed significant improvements in urinary symptoms and UTI recurrence, with no serious adverse events reported.
  4. Mean UTI frequency at 12 months was 0.6 episodes in Group A and 0.7 in Group B, with no significant intergroup difference.
  5. The study highlights the lack of standardized protocols for intravesical GAG therapy despite its growing use in managing recurrent UTIs.
...more

Frontiers In Oncology

  • September 7, 2026
Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam
  • Thi Hong Duc Phan
  • Hoang Quy Nguyen
  • September 7, 2026
  1. The study evaluated 107 patients with HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors and endocrine therapy.
  2. Median progression-free survival (PFS) was 28.0 months, with 12-month and 24-month PFS rates of 66.4% and 54.1%, respectively.
  3. Overall survival (OS) rates at 12 and 24 months were 88.8% and 87.8%, with median OS not yet reached during the study.
  4. Grade 3–4 neutropenia occurred in 58.8% of patients, all managed with dose adjustments, and no cases of febrile neutropenia were reported.
  5. The findings align with previous clinical trials, indicating favorable efficacy and tolerability of CDK4/6 inhibitors in this patient population.
...more

Dermatology And Therapy

  • September 7, 2026
Chronobiology in Dermatology: Exploring the Role of Circadian Rhythms in Skin Health and Treatment
  • Diala Haykal
  • September 7, 2026

Objective: To integrate current knowledge of the molecular architecture underlying the cutaneous circadian clock and assess the connection between circadian reg

...more

Frontiers In Immunology

  • September 7, 2026
Reevaluating Immunotherapy in Colorectal Cancer Liver Metastases: The Role of the Hepatic Metastatic Microenvironment Beyond Mismatch Repair
  • Lei Yang
  • Yuehua Liang
  • Wenqiang Wang
  • Jingjing Li
  • Bo Jia
  • Min Fu
  • Xialin Xie
  • Qian Chen
  • September 7, 2026
  1. dMMR/MSI-H status is the primary biomarker for immunotherapy in metastatic colorectal cancer, showing durable benefits with pembrolizumab.
  2. Active hepatic disease is linked to poorer outcomes in checkpoint therapy, but findings are inconsistent and do not warrant withholding treatment.
  3. Clinical data indicate that liver metastases correlate with reduced disease control and diminished benefits from checkpoint inhibitors.
  4. The liver's immunologically active environment may deplete tumor-specific T cells and impair T-cell activation, affecting immunotherapy efficacy.
  5. Active colorectal liver metastases may act as treatment-effect modifiers rather than established predictive biomarkers for immunotherapy.
...more

Frontiers In Immunology

  • September 7, 2026
Clinical Case Study: Efficacy of Dupilumab as a Steroid-Sparing Treatment for Refractory Anti-p200 Pemphigoid in a Patient with Multiple Comorbidities
  • Aikaterini Kyriakou
  • Christos Minas
  • Antonios Fantakis
  • Athanasia Tsaousi
  • Anastasia Tsitlakidou
  • Parthena Meltzanidou
  • Anthi-Maria Lazaridi
  • Alexandra Fleva
  • Anastasia Giannakou
  • Elisavet Lazaridou
  • Aikaterini Patsatsi
  • September 7, 2026
  1. Anti-p200 pemphigoid is a rare autoimmune blistering disease with limited management evidence and often resembles bullous pemphigoid.
  2. A 49-year-old woman with refractory anti-p200 pemphigoid experienced significant corticosteroid toxicity after failing high-dose prednisone and dapsone.
  3. Dupilumab was initiated as a steroid-sparing treatment, leading to substantial improvement in pruritus and near-complete remission within two months.
  4. After six months of dupilumab treatment, the patient maintained disease control and successfully tapered prednisone from 60 mg/day to 2.5 mg/day.
  5. No treatment-related adverse events were observed during the six-month follow-up after starting dupilumab.
...more

Frontiers In Immunology

  • September 7, 2026
A Pilot Case Series Investigating the Efficacy of Sequential Stereotactic Body Radiotherapy and Tislelizumab Following Platinum-Doublet Chemotherapy in Patients with Stage IIIB/C–IV Non-Squamous Non-Small Cell Lung Cancer
  • Shanshan Li
  • Feng Du
  • Changjun Leng
  • Jianjian Dou
  • Jian Shi
  • Yan Zhang
  • Feifei Lu
  • Qiang Wang
  • September 7, 2026
  1. This pilot case series included patients with unresectable stage IIIB/C–IV non-squamous NSCLC lacking actionable driver mutations.
  2. The study reported a 1-year progression-free survival rate of 25% and a median overall survival of 26.89 months.
  3. Treatment-related adverse events occurred in all patients, with 62.5% experiencing grade ≥3 adverse events.
  4. The best overall response rate was 87.5%, with 7 patients achieving partial response and 1 achieving stable disease.
  5. The findings are preliminary and cannot support definitive conclusions or clinical recommendations without further research.
...more

Frontiers In Oncology

  • September 7, 2026
Utilizing DCE-MRI Habitat Imaging to Distinguish Between Luminal and Non-Luminal Breast Cancer Subtypes: Findings from a Dual-Center Investigation
  • Zhang Qing
  • Qin Xiao-Tao
  • Zhou Xia
  • Zhang Xiu-Lan
  • Peng Jie
  • Li Yun
  • Wang Wei-Bing
  • September 7, 2026
  1. The study investigated DCE-MRI-based habitat imaging for distinguishing luminal from non-luminal breast cancer subtypes.
  2. Data were collected from 396 breast cancer patients across two centers, with various machine learning models developed for analysis.
  3. The stacking model achieved the highest AUC of 0.840, outperforming habitat and conventional radiomics models.
  4. Calibration curves indicated good calibration for the stacking model, and decision curves showed favorable net clinical benefit.
  5. Habitat imaging enhances the quantification of intratumoral heterogeneity, providing a noninvasive assessment of tumor characteristics.
...more

Frontiers In Oncology

  • September 7, 2026
Impact of the COVID-19 Pandemic on Surgical Volume and Postoperative Survival in Oncology: A Retrospective Study Across a Regional German Hospital Network
  • Antonia L. Stengler
  • Jörg Kleeff
  • Kerstin Lorenz
  • Nadja Weigert
  • Sandra Adam
  • Simon Rieder
  • Ulrich Ronellenfitsch
  • September 7, 2026
  1. The study evaluated oncological surgical procedures across pre-pandemic, pandemic, and post-pandemic periods in a regional German hospital network.
  2. A total of 2871 oncological surgeries were analyzed, with surgical volume peaking in January 2021 and reaching a low in April 2020.
  3. During the pandemic, UICC stage IV disease increased to 26.8%, compared to 23.9% pre-pandemic and 24.2% post-pandemic.
  4. Kaplan–Meier analysis indicated a trend toward reduced postoperative overall survival during the pandemic period.
  5. After adjusting for various factors, the hazard of death was lower in the pre-pandemic cohort compared to the pandemic cohort.
...more

Frontiers In Cardiovascular Medicine

  • September 7, 2026
Complete thoracoscopic removal of a catheter-associated thrombus in the right atrium: a case study
  • Siqi He
  • Jilu Lang
  • Chuang Mei
  • Yuanxiang Wen
  • Zhifeng Xu
  • September 7, 2026
  1. Totally implantable venous access ports (TIVAPs) are used for chemotherapy but can lead to catheter-related right atrial thrombus (CRAT).
  2. A breast cancer patient developed a right atrial thrombus after TIVAP use, which was not resolved by anticoagulation therapy.
  3. Multimodality imaging was crucial for identifying the thrombus and planning the surgical intervention.
  4. Totally thoracoscopic beating-heart thrombectomy was performed successfully to remove the thrombus.
  5. The case highlights the safety and feasibility of thoracoscopic surgery for CRAT with favorable clinical outcomes.
...more

Frontiers In Immunology

  • September 7, 2026
Preoperative Inflammatory-Lymphocyte Recovery Profile and Its Association with Pathological Outcomes in Resected Osteosarcoma: A Retrospective Analysis
  • Yang Liu
  • Hua Huang
  • Ke Yang
  • Daxin Gao
  • Tian Hao
  • Haiyu Zhou
  • Yonghong Huang
  • September 7, 2026
  1. In a study of 162 osteosarcoma patients, 54.3% exhibited poor pathological response after neoadjuvant chemotherapy.
  2. Patients were categorized into three recovery phenotypes: favorable recovery, intermediate recovery, and persistent recovery failure.
  3. Persistent recovery failure was significantly associated with poor pathological response, with an odds ratio of 5.72.
  4. The standardized risk of poor pathological response was 75.7% in the persistent failure group compared to 37.2% in the favorable recovery group.
  5. The study suggests that preoperative inflammatory-lymphocyte recovery phenotype may be linked to pathological outcomes in osteosarcoma.
...more

Frontiers In Immunology

  • September 7, 2026
Pulmonary Complications in a Child with Kawasaki Disease Shock Syndrome: A Case Study
  • Xuhua Xia
  • Jiwei Zhou
  • Lan Chen
  • Lei Zhang
  • September 7, 2026
  1. Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children, with Kawasaki disease shock syndrome (KDSS) being a severe complication.
  2. Pulmonary complications in KD are rare, but may include pneumonia, pulmonary nodules, and respiratory distress, which can necessitate mechanical ventilation.
  3. The case study describes a 9-year-old boy with KDSS who developed acute dyspnea during intravenous immunoglobulin (IVIG) treatment, requiring urgent intervention.
  4. Chest CT revealed multiple exudative lesions and consolidation in the lungs, while bronchoscopy identified acute endobronchitis in the patient.
  5. The patient achieved complete recovery after aggressive management, with no signs of coronary dilatation or pulmonary fibrosis at follow-up.
...more

Frontiers In Immunology

  • September 7, 2026
The Role of the PLA2G2F/Lysoplasmalogen Pathway in Connecting Epidermal Lipid Metabolism to Type 2 Inflammatory Responses and Pruritus in Atopic Dermatitis
  • Yoshimi Miki
  • Natsumi Higashisaka
  • Honami Inubushi
  • Niki Hirabayashi
  • Kanji Watanabe
  • Saho Fukui
  • Masayoshi Onitsuka
  • Chiaki Fukaura
  • Mariko Ogawa-Momohara
  • Kana Tanahashi
  • Yuki Nagasaki
  • Takuya Takeichi
  • Masashi Akiyama
  • Makoto Murakami
  • Kei Yamamoto
  • September 7, 2026
  1. Atopic dermatitis is characterized by type 2 immune responses, intense pruritus, and disrupted lipid metabolism.
  2. PLA2G2F, induced by type 2 cytokines, produces lysoplasmalogen, contributing to atopic dermatitis exacerbation and itch.
  3. Genetic deletion of Pla2g2f in mice reduced IL-33 expression, epidermal hyperplasia, and type 2 inflammation without altering neuronal function.
  4. Topical PLA2 inhibitors or breakdown of P-LPE reduced itch in wild-type mice, while exogenous P-LPE increased scratching in Pla2g2f-deficient mice.
  5. Higher P-LPE concentrations in the stratum corneum correlate with disease severity in atopic dermatitis patients, indicating its potential as a biomarker.
...more

Frontiers In Medicine

  • September 7, 2026
Transforming Metabolic Interference into Homeostatic Recovery: Modifying Hepatic Stellate Cell Energy Dynamics for the Reversal of Liver Fibrosis
  • Xinyu Lu
  • Zilong Li
  • September 7, 2026
  1. Metabolic reprogramming in hepatic stellate cells (HSCs) is a key factor in liver fibrosis progression, involving complex remodeling of metabolic networks.
  2. Lactate from glycolysis acts as an epigenetic signal, influencing fibrogenic gene expression in activated HSCs.
  3. Activated HSCs can transmit fibrotic characteristics to neighboring cells via GLUT1-containing exosomes, demonstrating metabolic crosstalk.
  4. HSC activation shows stage-specific metabolic vulnerabilities, with distinct metabolic states during early and full activation.
  5. Future anti-fibrotic strategies should focus on restoring metabolic homeostasis and utilize selective metabolic modulators to reverse HSC activation.
...more